Moleculin Biotech (LSE:0K2H) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

0K2H Overzicht aandelen

Moleculin Biotech, Inc., een farmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van kandidaat-geneesmiddelen voor de behandeling van kankers en virussen.

Over het bedrijf

0K2H fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft geen betekenisvolle marktkapitalisatie ( $8M )

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 1 meer risico

Moleculin Biotech, Inc. Concurrenten

ProBiotix Health

OFEX:PBX

UK£6.7m

Genflow Biosciences

LSE:GENF

UK£7.2m

Synairgen

AIM:SNG

UK£7.6m

Roquefort Therapeutics

LSE:ROQ

UK£4.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Moleculin Biotech
Historische aandelenkoersen
Huidige aandelenkoers	US$2.43
52 Week Hoogtepunt	US$14.85
52 Week Laag	US$2.28
Bèta	1.86
11 maand verandering	-2.21%
3 maanden verandering	-29.91%
1 Jaar Verandering	-67.66%
33 jaar verandering	-94.22%
5 jaar verandering	n/a
Verandering sinds IPO	-98.63%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0K2H	GB Biotechs	GB Markt
7D	0%	0.9%	-0.8%
1Y	-67.7%	-16.8%	9.2%

Rendement versus industrie: 0K2H presteerde slechter dan de UK Biotechs -sector, die het afgelopen jaar een rendement van -15.8 % opleverde.

Rendement versus markt: 0K2H presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 8.5 % opleverde.

Prijsvolatiliteit

Is 0K2H's price volatile compared to industry and market?
0K2H volatility
0K2H Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van 0K2H is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0K2H in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	18	Wally Klemp	moleculin.com

Moleculin Biotech, Inc, een farmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van kandidaat-geneesmiddelen voor de behandeling van kankers en virussen. Het belangrijkste kandidaat-geneesmiddel is Annamycine, dat zich in Fase 1B/2 van klinische studies bevindt voor de behandeling van recidief of refractaire acute myeloïde leukemie (AML) en naar de longen uitgezaaide weke delen sarcomen. Het bedrijf ontwikkelt ook WP1066, een immuun/transcriptiemodulator ontworpen om gefosforyleerde signaaltransducer en activator van transcriptie en andere oncogene transcriptiefactoren te remmen gericht op hersentumoren, alvleesklierkanker en andere kankers.

Moleculin Biotech, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Moleculin Biotech zich tot de beurswaarde?
0K2H fundamentele statistieken
Marktkapitalisatie	US$7.00m
Inkomsten(TTM)	-US$25.17m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is 0K2H overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0K2H resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$25.17m
Inkomsten	-US$25.17m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-8.85
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0K2H op de lange termijn?

Bekijk historische prestaties en vergelijking

0K2H Overzicht aandelen

Beloningen

Risicoanalyse

Moleculin Biotech, Inc. Concurrenten

OFEX:PBX

UK£6.7m

LSE:GENF

UK£7.2m

AIM:SNG

UK£7.6m

LSE:ROQ

UK£4.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Recent updates

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Biotech, Inc. Receives IND Clearance to Conduct Phase 1 Study of WP1066 for Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc., Annual General Meeting, May 26, 2022

Moleculin Biotech, Inc. Announces Presentation of Positive Preclinical Annamycin Data At the AACR 2022 Annual Meeting

Moleculin Biotech, Inc. Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

High number of new and inexperienced directors

Moleculin Biotech, Inc. Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

High number of new and inexperienced directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf